Clinical Trial Update: OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of OSI-906 in combination with gemcitabine and erlotinib for metastatic pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• OSI-906 (OSI-906)
• Tarceva (erlotinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Pancreatic Cancer, Metastatic | Phase 1, Phase 2 | Status: WITHDRAWN